BeiGene
North America, Massachusetts, United States, Cambridge
Description
BeiGene is a global oncology company.
Investor Profile
BeiGene has made 7 investments, with 1 in the past 12 months and 14% as lead.
Stage Focus
- Series A (43%)
- Seed (29%)
- Series B (14%)
- Post Ipo Equity (14%)
Country Focus
- United States (71%)
- China (29%)
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
Industry Focus
- Biotechnology
- Medical
- Life Science
- Health Care
- Oncology
- Pharmaceutical
- Therapeutics
- Biopharma
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'/%3e%3cuse xlink:href='%23a' transform='rotate(144 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(216 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(288 450 300)'/%3e%3c/svg%3e)
